论文部分内容阅读
目的探讨基于扶正解毒消积方的中西医结合方案对原发性肝癌的临床疗效及预后的影响。方法将68例原发性肝癌患者分为中西医结合组(西医综合治疗+扶正解毒消积方加减)和西医治疗组(西医综合治疗)各34例,观察两组治疗前后肝功能、甲胎蛋白和凝血酶原活动度情况以及实体瘤疗效、肝功能Child-Pugh分级及生存率。结果治疗后中西医结合组患者血清白蛋白(ALB)水平较治疗前明显升高,且高于西医治疗组治疗后(P<0.05)。治疗后中西医结合组实体瘤缓解率(33.33%)和稳定率(87.88%)均高于西医治疗组的17.24%和62.68%(P<0.05)。两组治疗后Child-Pugh分级比较差异无统计学意义(P>0.05)。治疗后中西医结合组生存率为97.1%,西医治疗组为85.3%,两组比较差异无统计学意义(P>0.05)。结论基于扶正解毒消积方的中西医结合方案治疗能够控制原发性肝癌的复发和进展,提高患者的生存时间。
Objective To investigate the clinical efficacy and prognosis of hepatocellular carcinoma (HCC) based on the combination of traditional Chinese medicine and western medicine based on Fuzheng Jiedu Decoction. Methods Sixty-eight patients with primary hepatocellular carcinoma (HCC) were divided into two groups (34 cases in each group), and the other groups were treated with the combination of western medicine and traditional Chinese medicine (Fuzheng Jiedu Decoction). Western medicine treatment group (34 cases) Fetoprotein and prothrombin activity as well as the efficacy of solid tumors, liver function Child-Pugh classification and survival rate. Results After treatment, serum albumin (ALB) level in patients with integrated traditional Chinese and western medicine was significantly higher than that before treatment and higher than that in western medicine group (P <0.05). The remission rate (33.33%) and stabilization rate (87.88%) of solid tumor in the combination of traditional Chinese medicine and western medicine group after treatment were both 17.24% and 62.68% (P <0.05) higher than that of Western medicine group. There was no significant difference in Child-Pugh classification between the two groups (P> 0.05). After treatment, the survival rate of integrated traditional Chinese and western medicine group was 97.1%, while that of western medicine group was 85.3%. There was no significant difference between the two groups (P> 0.05). Conclusion The combination of traditional Chinese medicine and western medicine based on Fuzheng Jiedu Decoction can control the recurrence and progression of primary liver cancer and improve the survival time of patients.